Stockscreener 앱 받기
22.44
1.24%
-0.06
전일 마감가:
$22.50
열려 있는:
$22.76
하루 거래량:
45,488
Relative Volume:
0.82
시가총액:
$999.51M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.71%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$21.75
$23.30
1주일 범위
$21.45
$25.32
52주 변동 폭
$18.62
$26.34
Septerna Inc Stock (SEPN) Company Profile
SEPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SEPN | 22.43 | 999.51M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.97 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 753.71 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.98 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.06 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.61 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
JPMorgan Chase & Co. Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna, Inc. Reports Q3 2024 Financials and Progress - TipRanks
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Septerna initiated with an Overweight at JPMorgan - Yahoo Finance
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Australia
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Nigeria
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Now Covered by Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
JPMorgan Chase & Co. Initiates Coverage on Septerna (NASDAQ:SEPN) - MarketBeat
Wells Fargo & Company Initiates Coverage on Septerna (NASDAQ:SEPN) - MarketBeat
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com UK
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering - ForexTV.com
Ra Capital Management buys $75 million in Septerna stock By Investing.com - Investing.com Australia
Ra Capital Management buys $75 million in Septerna stock - Investing.com
IPO Radar: Septerna, Swiggy and Horizon Robotics - The Armchair Trader
Septerna sees $11.7 million in stock purchases by Third Rock Ventures - Investing.com South Africa
IPO Roundup: Brazil Potash, Septerna and more (NYSEARCA:IPO) - Seeking Alpha
Septerna proposes terms for upsized $175M IPO - MSN
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
Septerna’s GPCRs draw strong demand in $288M IPO - BioCentury
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Hedge Funds, Asset Managers Turn Dollar Bulls on Election Risks - Yahoo Finance
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
Septerna Shares Rise 29% on First Trading Day - MarketWatch
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - MedCity News
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut - KFGO
Septerna Shares Jump 42% After IPO Shows Biotech Still Hot - AllSides
Goodwin, Cooley Guide Septerna's Upsized $288M IPO - Law360
Septerna's $288M IPO is another sign of the market warming to biotech investment - Fierce Biotech
Septerna Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Septerna Rings the Opening Bell - Nasdaq
MicroStrategy Touches New Highs as Trading Volume Relative to Nvidia Surges - Yahoo Finance
Septerna Prices Upsized 16M Share IPO at $18/sh By Investing.com - Investing.com Nigeria
Septerna Prices Upsized 16M Share IPO at $18/sh - Investing.com
Septerna Shares Set for Trading Debut After Upsized IPO - MarketWatch
Goldman-backed drug developer Septerna raises $288mln in US IPO - ZAWYA
Septerna Inc (SEPN) 재무 분석
Septerna Inc (SEPN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):